Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today ...

Aurobindo Pharma has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride extended-release tablets for the ...

Lupin launches generic dapagliflozin and metformin tablets in US after USFDA approval, offering a bioequivalent alternative ...

LAS VEGAS – Dapagliflozin significantly improved glycemic control and was well tolerated among treatment-naïve patients with type 2 diabetes and those unresponsive to prior treatment with glimepiride ...

Lupin announced the launch of Dapagliflozin and Metformin Hydrochloride extended-release tablets in the U.S., in strengths of 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, following ...

Pharmaceutical giant Lupin Ltd has launched its generic anti-diabetic medicine in the US, following approval from the country ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Dapagliflozin was approved by FDA for children and ...

The NICE Centre for Guidelines is currently conducting a partial update of NICE guideline 28 (NG28) Type 2 diabetes in adults: management. NICE is updating our recommendations on drug therapy. The ...

Combining dapagliflozin with calorie restriction achieved a greater type 2 diabetes (T2D) remission rate and significant changes in body fat and metabolic risk factors than calorie restriction alone.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

MUMBAI, India and NAPLES, Fla., April 8, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that ...